Walnut Creek, CANCT06977581Now EnrollingIRB Ready

Asthma Clinical Trial in Walnut Creek, CA

Access cutting-edge asthma treatment through this phase 2 clinical trial at a research site in Walnut Creek. Study-provided care at no cost to qualified participants.

Sponsored by Pfizer

Quick Self-Assessment

See if you qualify for this Walnut Creek location

Preparing your pre-screening questions…

Expert Care in Walnut Creek

Access asthma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related asthma treatment provided free

Apply for This Walnut Creek Location

Check if you qualify for this asthma clinical trial in Walnut Creek, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Walnut Creek

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Walnut Creek site if eligible
  4. 4Begin participation

About This Asthma Study in Walnut Creek

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking

Sponsor: Pfizer

Who Can Participate

Inclusion Criteria

Must meet the following asthma criteria:
History of persistent, moderate-to-severe asthma for at least 12 months prior to screening.
Must have experienced at least 1 asthma exacerbation requiring treatment with systemic steroids (oral or parenteral) for 3 days or more within 12 months of the screening visit.
At least 2 of the 3 pre-bronchodilator FEV1 values collected in the run-in period and the mean of the of pre-bronchodilator FEV1 values collected in the run-in period are ≥30% to \<80% of predicted normal values.
Positive bronchodilator responsiveness as evidenced by increase in FEV1 of at least 12% and 200 mL for spirometry conducted during screening period.
Maintenance (controller) treatment that minimally includes a medium to high dose ICS - LABA combination consistent with GINA Step 4/5 (either Track 1 or Track 2) for 12 months prior to the screening visit and at a stable dose for at least 3 months prior to the screening visit.
ACQ-5 score of ≥1.5 at screening visit and prior to randomization. Other Inclusion Criteria:
Body mass index between 18 40 kg/m2 at screening.

Exclusion Criteria

Medical Conditions:
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Evidence of lung disease(s) other than asthma, either clinical evidence, spirometry, or imaging (Chest X-ray, CT, MRI) within 12 months of the screening visit, as per local standard of care, including but not limited to: Chronic obstructive pulmonary disease, Other emphysematous lung disease such as alpha-1 antitrypsin disease, Cystic fibrosis, Emphysema, Idiopathic pulmonary fibrosis, Churg-Strauss syndrome, Allergic bronchopulmonary aspergillosis, Sarcoidosis
Diagnosed with any of the following acute or chronic infections or infection history:
Active helminth or parasitic infection requiring treatment within 2 weeks prior to screening;
Infection requiring hospitalization or systemic (parenteral) antimicrobial therapy within 60 days prior to Day 1;
Any infection judged to be an opportunistic infection or clinically significant by the investigator, within 6 months prior to Day 1. Prior/Concomitant Therapy:
Prior or current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s).
Prior or concurrent treatment with either approved or experimental biologic treatment (such as inhibitors of IL-4, IL-13, IL-33/ST2, IL-4Rα, TSLP, IL-5, OX40/OX40L or IgE) or targeted synthetic drugs (such as JAK inhibitors) for the treatment of asthma or other type 2 inflammatory diseases, including but not limited to: AD, EoE, CRS.
Treatment with any dose level of systemic (oral, injectable, or intraarticular) corticosteroids within 28 days of the screening visit.
Prior (within 12 weeks prior to screening) or planned concomitant treatment with immunoglobulin supplementation (eg, IV Ig or SC Ig).
History of anaphylaxis to antibody therapeutic or to PF-07275315 or to the excipients of the formulated drug products.
Bronchial thermoplasty within the previous 24 months. Prior/Concurrent Clinical Study Experience:
Administration of an investigational drug product within 30 days or 5 half lives preceding the screening visit (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Walnut Creek?

Yes, this clinical trial (NCT06977581) has an active research site in Walnut Creek, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Asthma Treatment Options in Walnut Creek, CA

If you're searching for asthma treatment options in Walnut Creek, CA, this clinical trial (NCT06977581) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Walnut Creek research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced asthma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all asthma clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Walnut Creek, CA

See all ankylosing spondylitis clinical trials recruiting in Walnut Creek — not just this study.

Browse Ankylosing Spondylitis Trials in Walnut Creek →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsAsthma TrialsPediatric Asthma TrialsModerate-to-Severe Asthma TrialsAll Conditions →

Ready to Join in Walnut Creek?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Walnut Creek, CA